Brianna Jones
Primary Care · Greenville, NCNPI 1760225908
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations.
Across 123 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$303
- Amgen$294
- AbbVie$247
- Novartis$164
- Pfizer$149
- GSK$98
- plus $714 from 18 others
What the payments were for
- Food & beverage$1,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $303 |
| Amgen | 29 | $294 |
| AbbVie | 18 | $247 |
| Novartis | 9 | $164 |
| Pfizer | 7 | $149 |
| GSK | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $84 |
| Tolmar, Inc. | 3 | $76 |
| Boehringer Ingelheim | 4 | $74 |
| Exact Sciences | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| AstraZeneca | 3 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Verity Pharmaceuticals Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Dexcom, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$1,968 in reported general payments places this provider in the 75th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 11 | $113 |
| Ciprofloxacin Hcl | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Other primary care in Greenville
- Kenzie Midgette DavisGreenville$6K
- Bradley JonesGreenville$4K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.